

Experiment Number: 88073-04
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**
Test Compound: 2',3'-Dideoxycytidine
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
Time Report Requested: 15:28:13
First Dose M/F: NA / NA
Lab: SRI

C Number:	C88073C
Lock Date:	07/25/1995
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 88073-04
 Test Type: 26-WEEK
 Route: GAVAGE
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
 Test Compound: 2',3'-Dideoxycytidine
 CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
 Time Report Requested: 15:28:13
 First Dose M/F: NA / NA
 Lab: SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Disposition Summary				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice		1		
Survivors				
Terminal Sacrifice	50	49	50	50
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Liver	(50)	(50)	(50)	(50)
Basophilic Focus			1	1
Inflammation, Chronic Active	4 [2.5]	1 [3.0]	2 [2.0]	2 [2.0]
Mixed Cell Focus				1
Necrosis, Focal	9 [2.4]	3 [2.7]	4 [1.8]	8 [2.8]
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(49)	(49)
Accessory Adrenal Cortical Nodule	1 [3.0]	1 [3.0]	1 [3.0]	2 [3.0]
Hypertrophy, Focal	3 [1.0]			
Adrenal Medulla	(49)	(50)	(49)	(49)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88073-04
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
Test Compound: 2',3'-Dideoxycytidine
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
Time Report Requested: 15:28:13
First Dose M/F: NA / NA
Lab: SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Hyperplasia			2 [2.0]	
Lymph Node	(0)	(0)	(1)	(0)
Lymph Node, Mesenteric	(49)	(50)	(50)	(50)
Atrophy		1 [2.0]		
Hematopoietic Cell Proliferation			1 [2.0]	
Spleen	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation		2 [1.5]	4 [1.0]	9 [1.3]
Thymus	(49)	(50)	(49)	(50)
Atrophy		2 [2.0]	8 [2.3]	
Hyperplasia		3 [2.0]	4 [1.8]	3 [2.0]
INTEGUMENTARY SYSTEM				
Skin	(0)	(0)	(0)	(1)
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar Epith, Hyperplasia				1 [1.0]
Hemorrhage	7 [1.9]		2 [1.0]	1 [1.0]
Metaplasia, Osseous			1 [1.0]	
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(0)	(0)	(1)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88073-04
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]
Test Compound:** 2',3'-Dideoxycytidine
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
Time Report Requested: 15:28:13
First Dose M/F: NA / NA
Lab: SRI

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88073-04
 Test Type: 26-WEEK
 Route: GAVAGE
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
 Test Compound: 2',3'-Dideoxycytidine
 CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
 Time Report Requested: 15:28:13
 First Dose M/F: NA / NA
 Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Disposition Summary				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice			3	4
Natural Death				1
Survivors				
Moribund Sacrifice				1
Terminal Sacrifice	50	50	47	44
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Liver	(50)	(50)	(50)	(50)
Inflammation, Chronic Active	2 [1.0]			
Mixed Cell Focus			1	
Necrosis, Focal	1 [1.0]	1 [1.0]		1 [1.0]
Mesentery	(0)	(0)	(0)	(1)
Fat, Necrosis				1 [2.0]
Pancreas	(0)	(0)	(0)	(1)
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	2 [3.0]	2 [3.0]	2 [3.0]	2 [3.0]
Hyperplasia, Diffuse				1 [2.0]
Hyperplasia, Focal			1 [2.0]	
Adrenal Medulla	(48)	(50)	(50)	(50)
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88073-04
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
Test Compound: 2',3'-Dideoxycytidine
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
Time Report Requested: 15:28:13
First Dose M/F: NA / NA
Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
GENITAL SYSTEM				
Ovary	(50)	(50)	(50)	(50)
Amyloid Deposition			1 [2.0]	
Cyst		3 [3.0]	1 [3.0]	2 [2.0]
Uterus	(7)	(7)	(6)	(1)
Hyperplasia, Cystic	7 [2.3]	7 [2.0]	4 [2.3]	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia		1 [1.0]		
Lymph Node	(1)	(0)	(3)	(2)
Inguinal, Infiltration Cellular, Histiocyte	1 [3.0]			
Lymph Node, Mandibular	(0)	(0)	(2)	(4)
Lymph Node, Mesenteric	(50)	(50)	(50)	(49)
Spleen	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation	12 [1.4]	9 [1.4]	18 [1.2]	3 [1.7]
Pigmentation			1 [2.0]	
Thymus	(50)	(50)	(50)	(49)
Atrophy		6 [2.0]	10 [2.6]	1 [2.0]
Hyperplasia			1 [2.0]	
INTEGUMENTARY SYSTEM				
Skin	(0)	(2)	(3)	(2)
Epidermis, Hyperplasia			2 [2.0]	2 [1.5]
Inflammation, Chronic Active			1 [1.0]	
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
Brain	(0)	(0)	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88073-04
Test Type: 26-WEEK
Route: GAVAGE
Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**
Test Compound: 2',3'-Dideoxycytidine
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014
Time Report Requested: 15:28:13
First Dose M/F: NA / NA
Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Hemorrhage				1 [4.0]
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Hemorrhage	3 [1.7]			1 [2.0]
Inflammation, Chronic Active	1 [1.0]			
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(0)	(0)	(2)	(4)

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)